<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02516618</url>
  </required_header>
  <id_info>
    <org_study_id>R475-PN-1516</org_study_id>
    <nct_id>NCT02516618</nct_id>
  </id_info>
  <brief_title>Study of Fasinumab (REGN475) in Healthy Japanese and Caucasian Subjects</brief_title>
  <official_title>A Randomized, Double-Blind, Placebo-Controlled, Single-Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of Fasinumab in Healthy Japanese and Caucasian Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Regeneron Pharmaceuticals</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Regeneron Pharmaceuticals</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of the study is to assess the safety and tolerability of a single dose&#xD;
      of subcutaneous (SC) or intravenous (IV) administered fasinumab in healthy Japanese subjects.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>July 2015</start_date>
  <completion_date type="Actual">February 2016</completion_date>
  <primary_completion_date type="Actual">February 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary endpoint in the study is the incidence and severity of treatment emergent adverse events (TEAEs) in participants treated with fasinumab or placebo.</measure>
    <time_frame>Baseline to week 16 (End of Study)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Fasinumab serum concentrations over time</measure>
    <time_frame>Baseline to week 16 (End of Study)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Presence of anti-fasinumab antibodies over time</measure>
    <time_frame>Baseline to week 16 (End of Study)</time_frame>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Healthy Volunteers</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this cohort will receive dose 1 of Fasinumab or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this cohort will receive dose 2 of Fasinumab or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this cohort will receive dose 3 of Fasinumab or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this cohort will receive dose 4 of Fasinumab or placebo</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 5</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants in this cohort will receive dose 5 of Fasinumab or placebo</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fasinumab</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
    <other_name>REGN475</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_label>Cohort 4</arm_group_label>
    <arm_group_label>Cohort 5</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key Inclusion Criteria:&#xD;
&#xD;
          1. Healthy male or female Japanese and Caucasian volunteers ≥20 and ≤55 years of age at&#xD;
             the screening visit&#xD;
&#xD;
          2. Japanese subjects must:&#xD;
&#xD;
               -  Be first generation Japanese, defined as born in Japan and having 4 biologic&#xD;
                  grandparents who are ethnic Japanese&#xD;
&#xD;
               -  Have maintained a Japanese lifestyle since leaving Japan&#xD;
&#xD;
          3. Caucasian subjects must be Caucasian of European or Latin American descent&#xD;
&#xD;
          4. Have a Body Mass Index (BMI) ≤ 35&#xD;
&#xD;
          5. Be willing to refrain from taking NSAID medications (oral or topical) for 1 week prior&#xD;
             to receiving study drug and for 16 weeks after study drug administration&#xD;
&#xD;
        Key Exclusion Criteria:&#xD;
&#xD;
          1. History or presence at the screening visit of bone or joint disorders including but&#xD;
             not limited to osteoarthritis, avascular necrosis, destructive arthropathy, pathologic&#xD;
             fractures, osteonecrosis, rheumatoid arthritis, neuropathic joint arthropathy, lupus&#xD;
             erythematosus, or inflammatory joint diseases&#xD;
&#xD;
          2. History of joint-related events such as, but not limited to, total joint replacement&#xD;
             (TJR) surgery, patella dislocation, hip dislocation, knee dislocation, injury to&#xD;
             meniscus or knee ligaments (with or without surgical repair), or joint infections&#xD;
&#xD;
          3. Trauma to any joint in the 30 days prior to the screening visit&#xD;
&#xD;
          4. History of autonomic neuropathy, or diabetic neuropathy&#xD;
&#xD;
          5. Evidence of autonomic neuropathy&#xD;
&#xD;
          6. Presence of clinically relevant peripheral neuropathy&#xD;
&#xD;
          7. History or presence at the screening visit of orthostatic hypotension&#xD;
&#xD;
          8. History or evidence at screening of heart block&#xD;
&#xD;
          9. Resting heart rate of &lt;50 or &gt;100 beats per minute (bpm)&#xD;
&#xD;
         10. History of poorly controlled hypertension:&#xD;
&#xD;
         11. Congestive heart failure with NY Heart Classification of stage 3 or 4&#xD;
&#xD;
         12. History of myocardial infarction, acute coronary syndromes, or cerebrovascular&#xD;
             accident within 12 months prior to the screening visit&#xD;
&#xD;
         13. Significant concomitant illness such as, but not limited to, cardiac, renal,&#xD;
             neurological, endocrinological, GI, hepatic, metabolic or lymphatic disease that would&#xD;
             adversely affect the subject's participation in this study or interpretation of&#xD;
             safety/PK data&#xD;
&#xD;
         14. HIV, hepatitis B, or hepatitis C positive by serological testing at the screening&#xD;
             visit&#xD;
&#xD;
         15. History or presence of malignancy within 5 years prior to screening, except subjects&#xD;
             who have been treated successfully with no recurrence of basal or squamous cell&#xD;
             carcinoma of the skin (&lt; 1 year), in situ cervical cancer, or in situ ductal breast&#xD;
             cancer&#xD;
&#xD;
         16. Women of reproductive potential who have a positive serum pregnancy test result at the&#xD;
             screening visit, or a positive urine pregnancy test result at the baseline visit, or&#xD;
             who do not have their pregnancy test results at the baseline visit&#xD;
&#xD;
         17. Pregnant or breast-feeding women&#xD;
&#xD;
         18. Participation in any clinical research study evaluating another investigational drug&#xD;
             or therapy within 30 days or at least 5 half-lives of the investigational drug,&#xD;
             whichever is longer, prior to the day 1 visit&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Trial Management</last_name>
    <role>Study Director</role>
    <affiliation>Regeneron Pharmaceuticals</affiliation>
  </overall_official>
  <location>
    <facility>
      <address>
        <city>Glendale</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2016</verification_date>
  <study_first_submitted>July 31, 2015</study_first_submitted>
  <study_first_submitted_qc>August 3, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 6, 2015</study_first_posted>
  <last_update_submitted>May 10, 2016</last_update_submitted>
  <last_update_submitted_qc>May 10, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 12, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fasinumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

